SCHEMBL1476720

SCHEMBL1476720

O=C(C=Cc1ccccn1)Nc1cc(-c2ccco2)on1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.55
KMT2A Q03164 7/20 0.55
NPC1 O15118 7/20 0.55
SMN1; SMN2 Q16637 6/20 0.55
LMNA P02545 5/20 0.55
PKM P14618 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
ALDH1A1 P00352 7/20 0.48
MAPT P10636 5/20 0.47
TSHR P16473 2/20 0.47
MEN1 O00255 5/20 0.44
KDM4E B2RXH2 5/20 0.44
POLB P06746 3/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
SCD5 Q86SK9 1/20 0.44
BLM P54132 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HSD17B10 Q99714 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12751455 1.00 RAB9A (0.55) RAB9AKMT2ANPC1SMN1; SMN2LMNA
SCHEMBL1476718 1.00 RAB9A (0.55) RAB9AKMT2ANPC1SMN1; SMN2LMNA
SCHEMBL1476514 0.83 ALDH1A1 (0.57) RAB9AKMT2ANPC1SMN1; SMN2LMNA
SCHEMBL1476512 0.83 ALDH1A1 (0.57) RAB9AKMT2ANPC1SMN1; SMN2LMNA
SCHEMBL12751518 0.83 ALDH1A1 (0.57) RAB9AKMT2ANPC1SMN1; SMN2LMNA
SCHEMBL1474594 0.82 RAB9A (0.51) RAB9AKMT2ANPC1SMN1; SMN2LMNA
SCHEMBL12751473 0.82 RAB9A (0.51) RAB9AKMT2ANPC1SMN1; SMN2LMNA
SCHEMBL1474595 0.82 RAB9A (0.51) RAB9AKMT2ANPC1SMN1; SMN2LMNA
SCHEMBL1474767 0.80 MEN1 (0.55) RAB9AKMT2ANPC1SMN1; SMN2LMNA
SCHEMBL1474766 0.80 MEN1 (0.55) RAB9AKMT2ANPC1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 RAB9A 2013/4885KMT2A 4661/4885NPC1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.